SEC 13F Intelligence

Managers / Q3 2023 · view latest →

Avidity Partners Management LP

CIK 0001791827 · 2828 N HARWOOD STREET, SUITE 1220, DALLAS, TX, 75201 · 214-550-1822

Reported Value
$2.5B
Q3 2023
Positions
83
Filings on Record
29
2019–present window
Filed
Nov 14, 2023
original filing

Summary

Avidity Partners Management LP reported $2.5B in U.S.-listed holdings across 83 positions for Q3 2023.

Its largest position, BSX, represents 4.4% of the portfolio.

Compared with Q2 2023, the fund opened 13 new positions and exited 23.

Portfolio Metrics

Turnover
+29.8%
vs prior filed quarter
Top-10 Concentration
+29.6%
share of reported value
Largest Position
+4.4%
Boston Scientific
New / Exited
13 / 23
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $0Q4 ’19Q1 ’20: $0Q2 ’20: $1.6BQ3 ’20: $2.2BQ4 ’20: $3.1BQ4 ’20Q1 ’21: $3.6BQ2 ’21: $3.7BQ3 ’21: $4.5BQ4 ’21: $4.7BQ4 ’21Q1 ’22: $4.8BQ2 ’22: $4.4BQ3 ’22: $4.9BQ4 ’22: $4.6BQ4 ’22Q1 ’23: $3.0BQ2 ’23: $2.9BQ3 ’23: $2.5BQ4 ’23: $2.7BQ4 ’23Q1 ’24: $3.1BQ2 ’24: $2.4BQ3 ’24: $2.0BQ4 ’24: $1.0BQ4 ’24Q1 ’25: $525MQ2 ’25: $502MQ3 ’25: $439MQ4 ’25: $347MQ4 ’25Q1 ’26: $936Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 81.8%Other: 11.7%ADR: 6.5%Equity WRT: 0.0%
  • Common Stock · 81.8% · $2.0B
  • Other · 11.7% · $289M
  • ADR · 6.5% · $161M
  • Equity WRT · 0.0% · $8,954

Quarter-over-Quarter Changes full breakdown →

vs Q2 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
CITHE CIGNA GROUPNEW+207.7K207.7K+$59M$59M
UNHUNITEDHEALTH GROUP INCNEW+112.2K112.2K+$57M$57M
HUMHUMANA INCNEW+110.3K110.3K+$54M$54M
DHRDANAHER CORPORATIONNEW+176.6K176.6K+$44M$44M
ITCIEURINTRA-CELLULAR THERAPIES INCNEW+801.1K801.1K+$42M$42M
MIRMMIRUM PHARMACEUTICALS INCNEW+1.14M1.14M+$36M$36M
DC4DEXCOM INCNEW+377.7K377.7K+$35M$35M
HCAHCA HEALTHCARE INCNEW+114.8K114.8K+$28M$28M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2023

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BSXBOSTON SCIENTIFIC CORPhistory →COM4.39%$109M2.07M
2JAZZ PHARMACEUTICALS PLCSHS USD4.16%$103M797.5K
3BDXBECTON DICKINSON & COhistory →COM2.99%$74M286.8K
4NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.95%$73M652.1K
5MCKMCKESSON CORPhistory →COM2.91%$72M166.3K
6LEGNLEGEND BIOTECH CORPhistory →SPONSORED ADS2.62%$65M967.0K
7THCTENET HEALTHCARE CORPhistory →COM NEW2.56%$64M963.8K
8CITHE CIGNA GROUPhistory →COM2.39%$59M207.7K
9IDYAIDEAYA BIOSCIENCES INChistory →COM2.33%$58M2.14M
10UNHUNITEDHEALTH GROUP INChistory →COM2.28%$57M112.2K
11SRPTSAREPTA THERAPEUTICS INChistory →COM2.20%$55M450.0K
12HUMHUMANA INChistory →COM2.16%$54M110.3K
13ARVNARVINAS INChistory →COM2.07%$51M2.61M
14ACHCACADIA HEALTHCARE COMPANY INhistory →COM2.02%$50M715.0K
15KARUNA THERAPEUTICS INCCOM1.95%$48M286.7K
16REGNREGENERON PHARMACEUTICALShistory →COM1.92%$48M58.0K
17ZTSZOETIS INChistory →CL A1.84%$46M262.1K
18IMVTIMMUNOVANT INChistory →COM1.81%$45M1.17M
19MLTXMOONLAKE IMMUNOTHERAPEUTICShistory →CLASS A ORD1.78%$44M777.2K
20DHRDANAHER CORPORATIONhistory →COM1.76%$44M176.6K
21ZNTLZENTALIS PHARMACEUTICALS INChistory →COM1.70%$42M2.10M
22ITCIEURINTRA-CELLULAR THERAPIES INChistory →COM1.68%$42M801.1K
23SNDXSYNDAX PHARMACEUTICALS INChistory →COM1.65%$41M2.82M
24LLYELI LILLY & COhistory →COM1.62%$40M75.0K
25NTRANATERA INChistory →COM1.60%$40M899.0K
26ARGXARGENX SEhistory →SPONSORED ADR1.60%$40M80.6K
27SGRYSURGERY PARTNERS INChistory →COM1.58%$39M1.34M
28LNTHLANTHEUS HLDGS INChistory →COM1.56%$39M558.4K
29PCVXVAXCYTE INChistory →COM1.55%$39M756.2K
302655787DBLUEPRINT MEDICINES CORPhistory →COM1.52%$38M751.6K
31AKROAKERO THERAPEUTICS INChistory →COM1.51%$37M739.1K
32MIRMMIRUM PHARMACEUTICALS INChistory →COM1.45%$36M1.14M
33PRVAPRIVIA HEALTH GROUP INChistory →COM1.43%$36M1.55M
34DC4DEXCOM INChistory →COM1.42%$35M377.7K
35BIOHAVEN LTDCOM1.35%$33M1.29M
36RCKTROCKET PHARMACEUTICALS INChistory →COM1.31%$33M1.59M
37AMLXAMYLYX PHARMACEUTICALS INChistory →COM1.30%$32M1.76M
38IMGNEURIMMUNOGEN INChistory →COM1.23%$30M1.92M
39BIIBBIOGEN INChistory →COM1.19%$30M115.4K
40CRBUCARIBOU BIOSCIENCES INChistory →COM1.16%$29M6.05M
41ARWRARROWHEAD PHARMACEUTICALS INhistory →COM1.15%$29M1.06M
42HCAHCA HEALTHCARE INChistory →COM1.14%$28M114.8K
43NMRANEUMORA THERAPEUTICS INC.history →COM1.02%$25M1.80M
44GPCRSTRUCTURE THERAPEUTICS INChistory →SPONSORED ADS1.02%$25M500.0K
45UHSUNIVERSAL HLTH SVCS INChistory →CL B0.92%$23M182.0K
46CUREVAC N VCOM0.86%$21M3.12M
47AXSMAXSOME THERAPEUTICS INChistory →COM0.84%$21M296.8K
48RAREULTRAGENYX PHARMACEUTICAL INhistory →COM0.78%$19M544.0K
49PROTHENA CORP PLCSHS0.74%$18M382.3K
50RVMDREVOLUTION MEDICINES INChistory →COM0.73%$18M657.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026REVEALED$936M91May 13, 202613F-HRchanges · EDGAR ↗
Q4 2025$347M39Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$439M43Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$502M56Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$525M67May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$1.0B63Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$2.0B81Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$2.4B85Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$3.1B90May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$2.7B74Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$2.5B83Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$2.9B93Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$3.0B83May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$4.6B85Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$4.9B98Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$4.4B82Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$4.8B92May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$4.7B97Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$4.5B105Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$3.7B112Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$3.6B94May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$3.1B96Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$2.2B68Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.6B57Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$01May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$01Feb 14, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.